Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 5/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 3/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.31 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393674 | 0.79 | HTR2A (0.38) | PDE4DHTR2AHTR2CHTR2B | |
| SCHEMBL28968102 | 0.79 | PDE4D (0.38) | PDE4DTDP1PDE4ARIPK1PDE4B | |
| SCHEMBL3396275 | 0.78 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL311915 | 0.78 | ACHE (0.34) | — | |
| SCHEMBL3393879 | 0.78 | — | — | |
| SCHEMBL3395148 | 0.78 | KDM4E (0.30) | TDP1 | |
| SCHEMBL3392781 | 0.76 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL3393578 | 0.75 | SMN1; SMN2 (0.37) | THRATHRB | |
| SCHEMBL2581701 | 0.75 | PDE4D (0.47) | PDE4DHTR2AHTR2CHTR2BHTR7 | |
| SCHEMBL1096701 | 0.74 | PDE4B (0.39) | PDE4DHTR2AHTR2CHTR2BHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-7138401-B2 | 2-aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | HSP90AB2P, HSP90AB1, HSP90AA1 | PDE4D 3201/4885HTR2A 1322/4885HTR2C 1358/4885 |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | HSP90AB2P, HSP90AB1, HSP90AA1 | PDE4D 3201/4885HTR2A 1322/4885HTR2C 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.